Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 7/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 5/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23178023 | 0.83 | MCL1 (0.52) | MCL1DPP4CTSSCTSLCTSK | |
| SCHEMBL583353 | 0.80 | MCL1 (0.40) | MCL1DPP4TERTPOLB | |
| SCHEMBL1790228 | 0.79 | — | — | |
| SCHEMBL14590058 | 0.77 | — | — | |
| SCHEMBL583505 | 0.77 | MCL1 (0.38) | MCL1DPP4TERTPOLB | |
| SCHEMBL5418544 | 0.77 | — | — | |
| SCHEMBL5154225 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL10795924 | 0.77 | MCL1 (0.50) | MCL1DPP4TERTPOLBALDH1A1 | |
| SCHEMBL12472218 | 0.76 | MCL1 (0.40) | MCL1CTSSCTSLCTSKCTSB | |
| SCHEMBL21153346 | 0.75 | MCL1 (0.48) | MCL1DPP4TERTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| EP-2190838-A1 | CANNABINOID RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | MCL1 2183/4885DPP4 2243/4885CTSS 2390/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | MCL1 1380/4885DPP4 4399/4885CTSS 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.